Amanda C. O’Brien

Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII

Michael Recht, László Nemes, Michał Matysiak et al. · Haemophilia · 2009 · 93 citations

Medicine, Pharmacokinetics, Pharmacology +17

BDDrFVIII (Moroctocog alfa [AF‐CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study

Jerzy Windyga, L. Rusen, Ralph A. Gruppo et al. · Haemophilia · 2010 · 29 citations

Medicine, Hematology, Surgery +16

Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy

Ben J. Samelson-Jones, Spencer K. Sullivan, John E.J. Rasko et al. · Blood · 2021 · 27 citations

Medicine, Hematology, Gene Therapy +6

Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study

John E.J. Rasko, Benjamin J. Samelson‐Jones, Lindsey A. George et al. · New England Journal of Medicine · 2025 · 19 citations · Full text

Medicine, Hematology, Pharmaceutical Biotechnology +17